Consolidated Statement of Stockholders' Equity (USD $)	Total	Common Stock	Preferred Stock	Additional Paid-in Capital	Subscriptions Receivable	Accumulated Deficit during Development Stage	Noncontrolling Interest	Issued For Cash At Zero Point Zero One Dollars Per Unit	Issued For Cash At Zero Point Zero One Dollars Per Unit Common Stock	Issued For Cash At Ten Dollar Per Unit	Issued For Cash At Ten Dollar Per Unit Common Stock	Issued For Cash At Ten Dollar Per Unit Additional Paid-in Capital	Issued For Marketable Securities At Ten Dollar Per Unit	Issued For Marketable Securities At Ten Dollar Per Unit Common Stock	Issued For Marketable Securities At Ten Dollar Per Unit Additional Paid-in Capital	Issued For Cash At Fifteen Dollar Per Unit	Issued For Cash At Fifteen Dollar Per Unit Common Stock	Issued For Cash At Fifteen Dollar Per Unit Additional Paid-in Capital	Equity Issued in Business Combination	Equity Issued in Business Combination Common Stock	Equity Issued in Business Combination Additional Paid-in Capital	Issued As Gift For Ten Dollar And Ninety Cents Per Share	Issued As Gift For Ten Dollar And Ninety Cents Per Share Common Stock	Issued As Gift For Ten Dollar And Ninety Cents Per Share Additional Paid-in Capital	Issued As Stock Issuance Cost At Fifteen Dollar Per Unit	Issued As Stock Issuance Cost At Fifteen Dollar Per Unit Common Stock	Issued As Stock Issuance Cost At Fifteen Dollar Per Unit Additional Paid-in Capital	Exercised At Two Dollar Per Share	Exercised At Two Dollar Per Share Common Stock	Exercised At Two Dollar Per Share Additional Paid-in Capital	Exercised At Ten Dollar Per Share	Exercised At Ten Dollar Per Share Common Stock	Exercised At Ten Dollar Per Share Additional Paid-in Capital	Stock Issuance Cost Charged To Additional Paid In Capital	Stock Issuance Cost Charged To Additional Paid In Capital Additional Paid-in Capital	Exercised at $15.00 per share	Exercised at $15.00 per share Common Stock	Exercised at $15.00 per share Additional Paid-in Capital	Issued to purchase Insert Therapeutics share at $39.80 per share	Issued to purchase Insert Therapeutics share at $39.80 per share Common Stock	Issued to purchase Insert Therapeutics share at $39.80 per share Additional Paid-in Capital	Issued at $48.80 per share	Issued at $48.80 per share Common Stock	Issued at $48.80 per share Additional Paid-in Capital	Issued at $38.40 per share	Issued at $38.40 per share Common Stock	Issued at $38.40 per share Additional Paid-in Capital	Issued at $35.00 per share	Issued at $35.00 per share Common Stock	Issued at $35.00 per share Additional Paid-in Capital	Issued at $59.10 per share	Issued at $59.10 per share Common Stock	Issued at $59.10 per share Additional Paid-in Capital	Issued to purchase Calando Pharmaceuticals, Inc. at $51.70 per share	Issued to purchase Calando Pharmaceuticals, Inc. at $51.70 per share Common Stock	Issued to purchase Calando Pharmaceuticals, Inc. at $51.70 per share Additional Paid-in Capital	Issued at $57.80 per share, net	Issued at $57.80 per share, net Common Stock	Issued at $57.80 per share, net Additional Paid-in Capital	Issued for purchase of Carbon Nanotechnologies, Inc. at $37.70 per share	Issued for purchase of Carbon Nanotechnologies, Inc. at $37.70 per share Common Stock	Issued for purchase of Carbon Nanotechnologies, Inc. at $37.70 per share Additional Paid-in Capital	Issued at approximately $18.00 per share, net	Issued at approximately $18.00 per share, net Common Stock	Issued at approximately $18.00 per share, net Preferred Stock	Issued at approximately $18.00 per share, net Additional Paid-in Capital	Issued at $27.20 per share to Rice University	Issued at $27.20 per share to Rice University Common Stock	Issued at $27.20 per share to Rice University Preferred Stock	Issued at $27.20 per share to Rice University Additional Paid-in Capital	Issued at $28.30 per share to purchase shares of Unidym, Inc.	Issued at $28.30 per share to purchase shares of Unidym, Inc. Common Stock	Issued at $28.30 per share to purchase shares of Unidym, Inc. Preferred Stock	Issued at $28.30 per share to purchase shares of Unidym, Inc. Additional Paid-in Capital	Issued at $29.50 per share to purchase MASA Energy, LLC	Issued at $29.50 per share to purchase MASA Energy, LLC Common Stock	Issued at $29.50 per share to purchase MASA Energy, LLC Preferred Stock	Issued at $29.50 per share to purchase MASA Energy, LLC Additional Paid-in Capital	Issued at $21.90 per share to Unidym for the acquisition of Nanoconduction	Issued at $21.90 per share to Unidym for the acquisition of Nanoconduction Common Stock	Issued at $21.90 per share to Unidym for the acquisition of Nanoconduction Preferred Stock	Issued at $21.90 per share to Unidym for the acquisition of Nanoconduction Additional Paid-in Capital	Issued at $21.80 per share	Issued at $21.80 per share Common Stock	Issued at $21.80 per share Preferred Stock	Issued at $21.80 per share Additional Paid-in Capital	Issued at $5.50 per share to Unidym Stockholder in exchange for Unidym's shares	Issued at $5.50 per share to Unidym Stockholder in exchange for Unidym's shares Common Stock	Issued at $5.50 per share to Unidym Stockholder in exchange for Unidym's shares Preferred Stock	Issued at $5.50 per share to Unidym Stockholder in exchange for Unidym's shares Additional Paid-in Capital	Issued at $5.20 per share to TEL Ventures in exchange for Unidym's shares	Issued at $5.20 per share to TEL Ventures in exchange for Unidym's shares Common Stock	Issued at $5.20 per share to TEL Ventures in exchange for Unidym's shares Preferred Stock	Issued at $5.20 per share to TEL Ventures in exchange for Unidym's shares Additional Paid-in Capital	Issued at $3.00 per share	Issued at $3.00 per share Common Stock	Issued at $3.00 per share Preferred Stock	Issued at $3.00 per share Additional Paid-in Capital	Arrowheads increase in proportionate share of Calandos equity	Arrowheads increase in proportionate share of Calandos equity Preferred Stock	Arrowheads increase in proportionate share of Calandos equity Additional Paid-in Capital	Issued at $6.34 per share	Issued at $6.34 per share Common Stock	Issued at $6.34 per share Additional Paid-in Capital	Issued at $13.12 per share	Issued at $13.12 per share Common Stock	Issued at $13.12 per share Additional Paid-in Capital	Issued To Calando Stockholders In Exchange For Calando S Shares	Issued To Calando Stockholders In Exchange For Calando S Shares Common Stock	Issued To Calando Stockholders In Exchange For Calando S Shares Additional Paid-in Capital	Issued To Calando Stockholders In Exchange For Calando S Shares Noncontrolling Interest	Issued To Unidym Stockholders In Exchange For Unidyms Shares Common Stock	Issued To Unidym Stockholders In Exchange For Unidyms Shares Additional Paid-in Capital	Issued To Unidym Stockholders In Exchange For Unidyms Shares Noncontrolling Interest	Issued at $3.80 per share	Issued at $3.80 per share Common Stock	Issued at $3.80 per share Additional Paid-in Capital	Issued at $3.80 per share Subscriptions Receivable	Series D preferred stock issued for subscription in unidym	Series D preferred stock issued for subscription in unidym Subscriptions Receivable	Issuance of common stock for subscription Additional Paid-in Capital	Issuance of common stock for subscription Subscriptions Receivable	Issued at $3.70 per share	Issued at $3.70 per share Common Stock	Issued at $3.70 per share Additional Paid-in Capital	Issued at $4.00 per share	Issued at $4.00 per share Common Stock	Issued at $4.00 per share Additional Paid-in Capital	Issued at $6.23 per share	Issued at $6.23 per share Common Stock	Issued at $6.23 per share Additional Paid-in Capital	Issued at $5.11 per share	Issued at $5.11 per share Common Stock	Issued at $5.11 per share Additional Paid-in Capital	Issued at $2.76 per share	Issued at $2.76 per share Common Stock	Issued at $2.76 per share Additional Paid-in Capital	Issued at $2.76 per share Subscriptions Receivable	Issued Under Committed Capital Agreement Common Stock	Issued Under Committed Capital Agreement Additional Paid-in Capital	Issued at $2.26 per share	Issued at $2.26 per share Common Stock	Issued at $2.26 per share Additional Paid-in Capital	Issued at $2.12 per share	Issued at $2.12 per share Common Stock	Issued at $2.12 per share Additional Paid-in Capital	Issued at $4.49 per share	Issued at $4.49 per share Common Stock	Issued at $4.49 per share Preferred Stock	Issued at $4.49 per share Additional Paid-in Capital	Issued at $4.49 per share Subscriptions Receivable	Issued at $4.49 per share Accumulated Deficit during Development Stage	Issued at $4.49 per share Noncontrolling Interest	Issued at $1.83 per share	Issued at $1.83 per share Common Stock	Issued at $1.83 per share Preferred Stock	Issued at $1.83 per share Additional Paid-in Capital	Issued at $1.83 per share Subscriptions Receivable	Issued at $1.83 per share Accumulated Deficit during Development Stage	Issued at $1.83 per share Noncontrolling Interest	Preferred stock issued @ $1,000 per share	Preferred stock issued @ $1,000 per share Common Stock	Preferred stock issued @ $1,000 per share Preferred Stock	Preferred stock issued @ $1,000 per share Additional Paid-in Capital	Preferred stock issued @ $1,000 per share Subscriptions Receivable	Preferred stock issued @ $1,000 per share Accumulated Deficit during Development Stage	Preferred stock issued @ $1,000 per share Noncontrolling Interest
Beginning Balance Amount at Sep. 30, 2002
Issuance and sold of Common Stock									300,000		168,000
Stock issuances								3,000	3,000	1,680,000	1,680	1,678,320
Stock issuance cost charged to additional paid-in capital																																		(168,000)	(168,000)
Net income (loss)	(95,238)					(95,238)
Ending Balance Amount at Sep. 30, 2003	1,419,762	4,680		1,510,320		(95,238)
Ending Balance Shares at Sep. 30, 2003		468,000
Issuance and sold of Common Stock											47,500			50,000			660,879			70,553			15,000			35,623
Stock options exercised		7,500																											7,500			600
Stock issuances										475,000	475	474,525	500,000	500	499,500	9,913,182	6,609	9,906,573	(150,469)	706	(151,175)	162,750	163	162,587	534,344	356	533,988							(96,500)	(96,500)
Stock issuance cost charged to additional paid-in capital	(991,318)			(991,318)
Net income (loss)	(751,255)					(2,528,954)	1,777,699
Stock options exercised, Amount	15,000	75		14,925																								15,000	75	14,925	6,000	6	5,994
Stock-based compensation	175,653			175,653
Ending Balance Amount at Sep. 30, 2004	11,227,149	13,645		12,059,997		(2,624,192)	1,777,699
Ending Balance Shares at Sep. 30, 2004		1,363,155
Issuance and sold of Common Stock		1,250																																						50,226
Stock options exercised																																2,500					1,381,289
Stock issuances	50,000	12		49,988																																			2,000,000	502	1,999,498
Net income (loss)	(6,733,427)					(6,854,918)	121,491
Stock options exercised, Amount																															25,000	25	24,975			20,719,335	13,813	20,705,522
Stock-based compensation	508,513			508,513
Adjustments to additional paid in capital, reallocation of noncontrolling interest	230,087			230,087
Ending Balance Amount at Sep. 30, 2005	28,026,657	27,997		35,578,580		(9,479,110)	1,899,190
Ending Balance Shares at Sep. 30, 2005		2,798,419
Issuance and sold of Common Stock																																											20,485			1,500			559,000			2,536			20,838
Stock options exercised		11,579
Stock issuances																																										1,000,000	205	999,795	57,600	15	57,585	19,545,000	5,590	19,539,410	150,000	25	149,975	1,077,333	208	1,077,125
Net income (loss)	(19,961,961)					(18,997,209)	(964,752)
Stock options exercised, Amount	341,537	116		341,421
Stock-based compensation	1,369,478			1,369,478
Ending Balance Amount at Sep. 30, 2006	31,605,644	34,156		59,113,369		(28,476,319)	934,438
Ending Balance Shares at Sep. 30, 2006		3,414,359
Issuance and sold of Common Stock																																																										284,945			143,122
Stock options exercised		18,616
Stock issuances																																																									15,152,215	2,849	15,149,366	5,400,000	1,431	5,398,569
Net income (loss)	(30,712,947)					(29,931,118)	(781,829)
Stock options exercised, Amount	434,727	186		434,541
Stock-based compensation	2,175,544			2,175,544
Adjustments to additional paid in capital, reallocation of noncontrolling interest	2,401,394			2,401,394
Ending Balance Amount at Sep. 30, 2007	26,456,577	38,622		84,672,783		(58,407,437)	152,609
Ending Balance Shares at Sep. 30, 2007		3,861,042
Issuance and sold of Common Stock																																																																386,399				5,000				7,055				10,505				11,416				1,500
Stock options exercised		10,536
Stock issuances																																																															6,960,585	3,867		6,956,718	136,000	50		135,950	200,000	71		199,929	310,000	105		309,895	250,000	114		249,886	32,700	15		32,685
Net income (loss)	(27,241,639)					(27,089,030)	(152,609)
Stock options exercised, Amount	290,027	106		289,921
Stock-based compensation	3,187,397			3,187,397
Adjustments to additional paid in capital, reallocation of noncontrolling interest	1,720,962			1,720,962
Ending Balance Amount at Sep. 30, 2008	12,302,609	42,950		97,756,126		(85,496,467)
Ending Balance Shares at Sep. 30, 2008		4,293,452
Issuance and sold of Common Stock																																																																																								205,839				222,222				919,664
Stock issuances																																																																																							1,133,676	2,059		1,131,617	1,158,333	2,222		1,156,111	2,758,993	9,197		2,749,796
Net income (loss)	(19,308,392)					(19,308,392)
Stock-based compensation	2,676,170			2,676,170
Adjustments to additional paid in capital, reallocation of noncontrolling interest	16,297			16,297																																																																																															2,120,250		2,120,250
Reclassification of former Unidym mezzanine debt to equity	2,000,000			2,000,000
Issuance of Preferred Stock for Subscription in Unidym				300,000	(300,000)
Amortization of discount on Unidym Series D Preferred Stock				163,960		(163,960)
Ending Balance Amount at Sep. 30, 2009	4,857,936	56,428		110,070,327	(300,000)	(104,968,819)
Ending Balance Shares at Sep. 30, 2009		5,641,177
Issuance and sold of Common Stock		225,189																																																																																																					508,343			659,299			122,000			15,318
Stock options exercised		688
Stock issuances	1,066,050	2,250		1,063,600			200																																																																																															3,222,896	5,083	3,217,813	3,698,671	6,593	3,692,078		1,220	(160,667)	159,447	153	(1,435)	1,282
Net income (loss)	(6,957,038)					(5,774,048)	(1,182,990)
Stock options exercised, Amount	7,631	7		7,624
Stock-based compensation	1,582,149			1,582,149
Issuance of Preferred Stock for Subscription in Unidym																																																																																																																							300,000	300,000
Issuance of Unidym’s common stock to minority shareholders	300,000			245,345			54,655
Ending Balance Amount at Sep. 30, 2010	8,078,295	71,734		119,716,834		(110,742,867)	(967,406)
Ending Balance Shares at Sep. 30, 2010		7,172,014
Issuance and sold of Common Stock		8,656																																																																																																																		1,458,917
Stock options exercised		2,700
Stock issuances	43,279	87		43,192																																																																																																															4,643,684	14,574	4,629,110				900,000	(900,000)
Net income (loss)	(3,492,399)					(3,128,885)	(363,514)
Stock options exercised, Amount	13,884	27		13,857
Stock-based compensation	1,404,640			1,404,640
Adjustments to additional paid in capital, reallocation of noncontrolling interest				(849,707)			849,707
Issuance of Preferred Stock for Subscription in Unidym	1,618,509			1,618,509
Issuance of Unidym’s common stock to minority shareholders	254,275						254,275
Ending Balance Amount at Sep. 30, 2011	12,564,167	86,422		127,476,435	(900,000)	(113,871,752)	(226,938)
Ending Balance Shares at Sep. 30, 2011		8,642,286
Beginning Balance Amount at Aug. 31, 2011
Issuance and sold of Common Stock		1,191,473
Ending Balance Amount at Sep. 30, 2011		86,422			(900,000)
Ending Balance Shares at Sep. 30, 2011		8,642,286
Issuance and sold of Common Stock		138,158
Ending Balance Amount at Oct. 31, 2011
Beginning Balance Amount at Sep. 30, 2011	12,564,167	86,422		127,476,435	(900,000)	(113,871,752)	(226,938)
Issuance and sold of Common Stock		15,511																		1,217,159																																																																																																138,158								675,000			100,000			83,211			97,831			2,260,869			68,926
Stock options exercised	4,883	4,583
Stock issuances	50,406	16		50,390															6,147,830	9,332	6,138,498																																																																																														425,000	1,382	523,618	(100,000)					2,247,750	6,750	2,241,000	400,000	1,000	399,000	500,001	83	499,918	500,002	98	499,904	5,796,240	2,261	5,809,979	(16,000)	689	(689)																					1,015,000		1	1,014,999
Net income (loss)	(22,110,723)					(21,125,928)	(984,795)
Stock options exercised, Amount	23,833	45		23,788																																																																																																								8,000			8,000
Stock-based compensation	1,241,404			1,241,404
Fractional shares redeemed in reverse stock split		(131)
Preferred stock converted to common stock, shares		275,782	(1,015)
Preferred stock converted to common stock		276	(1)	(275)
Ending Balance Amount at Sep. 30, 2012	8,808,909	108,354		145,917,968		(134,997,680)	(1,203,733)
Ending Balance Shares at Sep. 30, 2012		13,579,185
Issuance and sold of Common Stock		1,825,079
Ending Balance Amount at Dec. 31, 2012
Beginning Balance Amount at Sep. 30, 2012	8,808,909	108,354		145,917,968	(1,016,000)	(134,997,680)	(1,203,733)
Issuance and sold of Common Stock																																																																																																																																														1,825,079			1,667,051			239,894							14,262,553								9,900
Stock options exercised	0
Stock issuances																																																																																																																																													2,678,573	1,826	2,676,747	2,240,936	1,667	2,239,269	986,049	240		985,809				25,459,499	14,263		25,445,236				9,900,000		10	9,899,990
Net income (loss)	(17,898,373)					(17,451,105)	(447,268)
Stock-based compensation	1,114,375			1,114,375
Subscription reversal, Shares		(267,444)
Subscription payment	16,000				16,000
Subscription reversal		(2,674)		(997,326)	1,000,000
Ending Balance Amount at Jun. 30, 2013	$ 33,305,968	$ 123,676	$ 10	$ 187,282,068		$ (152,448,785)	$ (1,651,001)
Ending Balance Shares at Jun. 30, 2013		31,306,318	9,900